Compounds > 5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil
Page last updated: 2024-11-06

5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID72308
CHEMBL ID288688
SCHEMBL ID9597854
MeSH IDM0245795

Synonyms (13)

Synonym
132774-46-0
1-(benzyloxymethyl)-6-phenylthio-5-ethyluracil
1-(benzyloxymethyl)-5-ethyl-6-phenylsulfanyl-pyrimidine-2,4-dione
CHEMBL288688 ,
5-ethyl-1-(phenylmethoxymethyl)-6-phenylsulfanylpyrimidine-2,4-dione
1-benzyloxymethyl-5-ethyl-6-phenylsulfanyl-1h-pyrimidine-2,4-dione
bdbm50004124
e-bpu cpd
5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil
2,4(1h,3h)-pyrimidinedione, 5-ethyl-1-((phenylmethoxy)methyl)-6-(phenylthio)-
SCHEMBL9597854
DTXSID10157771
1-(benzyloxymethyl)-5-ethyl-6-(phenylthio)uracil
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.00590.00040.61539.7000AID200003; AID200009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Activity0.00590.00091.30738.0000AID199980
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID200003Inhibition of HIV-1 reverse transcriptase at 37 degree Centigrade2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
AID154769Concentration required to inhibit replication of HIV-1 HTLV-IIIB strain in PBL (peripheral blood lymphocytes) cells1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID106964Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID231665CC50/EC50 ratio expressed as selectivity index(SI)1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID104274Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-11992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID225321Concentration required to reduce viability of mock-infected MT-4 cells1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID154767Concentration required to reduce viability of Mock infected PBL (peripheral blood lymphocytes) cells.1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID1125802Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect2014European journal of medicinal chemistry, Apr-22, Volume: 77QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method.
AID106587Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID235557Ratio of the EC50 against HIV-1 infected MT-4 cells and CC50 against mock infected MT-4 cells.1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID105892Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
AID106968Concentration required to inhibit replication of HIV-2 LAV-2rod strain in MT-4 cells1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID247810Inhibitory activity against human immunodeficiency virus type 12005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Topochemical model for prediction of anti-HIV activity of HEPT analogs.
AID200009Inhibitory concentration against HIV-1 reverse transcriptase1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
AID106592Concentration to required to reduce viability of Mock infected MT-4 cells1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID199980Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT)2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (55.56)18.2507
2000's3 (33.33)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.93 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		1.9810pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil: an anti-HIV agent; structure in first source. 6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil : A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by ethoxymethyl, isopropyl, and 3,5-dimethylbenzyl groups, respectively.		1.9910pyrimidone
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.6930cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil
1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil : A pyrimidone that is uracil in which positions 1, 5, and 6 are substituted by ethoxymethyl, isopropyl, and phenylsulfanyl groups, respectively.		3.150aryl sulfide;
pyrimidone
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.3820azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		2.0110acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine : A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.		3.2560aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil: inhibits human HIV-1; structure given in first source		3.2560
emivirine
emivirine: a non-nucleoside inhibitor of HIV-1 reverse transcriptase. emivirine : A pyrimidone that is uracil which is substituted at positions 1, 5 and 6 by ethoxymethyl, isopropyl, and benzyl groups, respectively. A non-nucleoside inhibitor of HIV-1 reverse transcriptase, emivirine was an unsuccessful experimental agent for the treatment of HIV.		2.6930pyrimidoneantiviral drug;
HIV-1 reverse transcriptase inhibitor
gw420867x
GW420867X: structure in first source		2.0110
e-ebu-dm
[no description available]		1.9910
12-hydroxynevirapine
12-hydroxynevirapine : A dipyridodiazepine that is nevirapine in which one of the hydrogens of the methyl group has been substituted by a hydroxy group. It is a metabolite of the anti-HIV drug, nevirapine.		2.4120aromatic primary alcohol;
cyclopropanes;
dipyridodiazepine		drug metabolite
r 82150
R 82150: structure given in first source; inhibits HIV-1 replication		2.0110
r-82913
R-82913: antiviral target on reverse transcriptase of HIV-1		2.0110
r 86183
[no description available]		2.0110
nsc 629243
NSC 629243: structure given in first source; an anti-HIV drug		2.0110
hby 097
HBY 097: a quinoxaline derivative		2.0110
trovirdine
trovirdine: HIV-1 reverse transcriptase inhibitor		2.0110
uc-781
[no description available]		2.0110
ly 73497
LY 73497: HIV-1 reverse transcriptase inhibitor; structure in first source		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials